专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2002016396A3 MAMMALIAN RH TYPE B GLYCOPROTEIN ION TRANSPORTER 审中-公开
公开(公告)号：WO2002016396A3
公开(公告)日：2002-02-28
申请号：PCT/US2001/025881
申请日：2001-08-17
申请人： THE NEW YORK BLOOD CENTER, INC. , HUANG, Cheng-Han , LIU, Zhi
发明人： HUANG, Cheng-Han , LIU, Zhi
IPC分类号： C12N5/10
摘要： The present invention provides nucleic acid sequences encoding novel mammalian nonerythroid Rh glycoprotein homologues, Rhbg including the human homologue RhBG. These RhBG, Rhbg glycoproteins are polytypic transporter-type proteins with 12 transmembrane domains and are predominantly expressed as a single major form in kidney, and as multiple forms in liver, skin and ovaries. Also provided are recombinant vectors and host vector systems containing these nucleic acid sequences, as well as fusion proteins incorporating Rhbg, RhBG or fragments of each. The invention further provides methods of detection of Rhbg and RhBG glycoproteins and also methods of detecting nucleic acids encoding Rhbg and RhBG.

2. 发明申请

WO2012125850A1 FC VARIANTS 审中-公开
公开(公告)号：WO2012125850A1
公开(公告)日：2012-09-20
申请号：PCT/US2012/029271
申请日：2012-03-15
申请人： AMGEN INC. , LIU, Zhi , KANNAN, Gunasekaran , YAN, Wei
发明人： LIU, Zhi , KANNAN, Gunasekaran , YAN, Wei
IPC分类号： C07K16/00
CPC分类号： C07K16/283 , A61K39/39558 , A61K45/06 , C07K16/00 , C07K2317/31 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/622 , C07K2317/72 , C07K2317/732
摘要： Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.
摘要翻译：公开了包含结合区和变体Fc区的含Fc蛋白，其可以比包含野生型Fc区的类似的含Fc蛋白更有效地引发一种或多种免疫效应子功能和/或与Fc受体结合。还公开了编码这种含Fc蛋白质的核酸，制备这种蛋白质的方法，以及利用这种蛋白质的治疗方法。

3. 发明申请

WO2010117873A2 PROGESTERONE SOLUTIONS FOR INCREASED BIOAVAILABILITY 审中-公开
标题翻译：用于增加生物利用度的PROGESTERONE解决方案
公开(公告)号：WO2010117873A2
公开(公告)日：2010-10-14
申请号：PCT/US2010/029625
申请日：2010-04-01
申请人： BANNER PHARMACAPS, INC. , LIU, Zhi , GOSANGARI, Saujanya, L. , TOOPS, Dana, S. , FATMI, Aqeel
发明人： LIU, Zhi , GOSANGARI, Saujanya, L. , TOOPS, Dana, S. , FATMI, Aqeel
IPC分类号： A61K9/48
CPC分类号： A61K9/4858 , A61K31/57 , A61K47/12 , A61K47/14
摘要： Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
摘要翻译：本文描述了用于疏水性药物（例如孕酮）的填充材料及其制备和使用方法。填充材料含有溶解在一种或多种脂肪酸中的疏水性药物。疏水性药物的浓度通常为填充材料重量的约7％至约50％。一种或多种脂肪酸的浓度为载体重量的约60％至约95％。制剂还含有一种有机酸和一种或多种药学上可接受的醇和一种或多种药学上可接受的中，长链脂肪酸的一，二或三酯的一种或两种。填充材料可以被包封在硬或软胶囊中。与悬浮在油中的微粉化孕酮相比，本文所述的制剂具有更高的溶解速率和更快的溶解出现，因此应该具有增加的体内生物利用度。

4. 发明申请

WO2010042499A1 STABLE SOLUTIONS OF ORLISTAT FOR PHARMACEUTICAL DOSAGE FORMS 审中-公开
标题翻译：用于药物剂型的ORLISTAT的稳定解决方案
公开(公告)号：WO2010042499A1
公开(公告)日：2010-04-15
申请号：PCT/US2009/059676
申请日：2009-10-06
申请人： BANNER PHARMACAPS, INC. , LIU, Zhi , TOOPS, Dana, S. , FATMI, Ageel, A.
发明人： LIU, Zhi , TOOPS, Dana, S. , FATMI, Ageel, A.
IPC分类号： A61K9/48 , A61K31/365
CPC分类号： A61K9/4858
摘要： Liquid orlistat-containing fill materials suitable for encapsulating in hard or soft capsules are described herein. The fill material contains orlistat dissolved in one or more medium chain triglycerides or medium chain partial triglycerides, one or more citrate esters, and combinations thereof. The fill material can also contain one or more pharmaceutically acceptable excipients. In one embodiment, the fili material is substantially free of surfactants. The fill material can be encapsulated in hard or soft, gelatin or non-gelatin capsules. The capsules may be coated to modify release of orlistat from the capsule. Alternatively, the fill material can be encapsulated in an enteric capsule, wherein the enteric polymer is a component of the capsule shell, rather than a coating over the capsule shell. The fill materials are stable at elevated temperatures over an extended period of time and allow for high loadings of orlistat (e.g., 20% w/w or higher).
摘要翻译：本文描述了适用于包封在硬胶囊或软胶囊中的含有液体奥利司他的填充材料。填充材料含有溶解在一种或多种中链甘油三酯或中链部分甘油三酸酯中的奥利司他，一种或多种柠檬酸酯及其组合。填充材料还可以含有一种或多种药学上可接受的赋形剂。在一个实施方案中，丝状物质基本上不含表面活性剂。填充材料可以包封在硬或软的明胶或非明胶胶囊中。胶囊可以被涂覆以改变从胶囊释放奥利司他。或者，填充材料可以包封在肠溶胶囊中，其中肠溶性聚合物是胶囊壳的组分，而不是胶囊壳上的涂层。填充材料在高温下在延长的时间内是稳定的并且允许高负荷的奥利司他（例如，20％w / w或更高）。

5. 发明申请

WO2008064163A2 POLYMER COATED DRUG-ION EXCHANGE RESINS AND METHODS 审中-公开
标题翻译：聚合物涂布的离子交换树脂和方法
公开(公告)号：WO2008064163A2
公开(公告)日：2008-05-29
申请号：PCT/US2007/085113
申请日：2007-11-19
申请人： MORTON GROVE PHARMACEUTICALS, INC. , CHEN, Bei , LIU, Zhi , GAO, Danchen , RAO, Mukti, S. , USAYAPANT, Arunya
发明人： CHEN, Bei , LIU, Zhi , GAO, Danchen , RAO, Mukti, S. , USAYAPANT, Arunya
CPC分类号： A61K31/137 , A61K9/0095 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K31/216 , A61K31/4355 , A61K31/439 , A61K47/585 , A61K47/60 , A61K47/6921
摘要： Included are compositions, and methods of making, coated controlled-release drug and ion exchange resin form complexes. Methacrylate coatings, which can be free of plasticizers particularly with Eudragit ® NE type polymer, are preferred to enhance the control of drug release from the drug-resin complexes. Liquid formulations including the coated resin forms and a chelating agent to inhibit degradation are also included.
摘要翻译：包括组合物和制备方法，包被的控释药物和离子交换树脂形成复合物。可以不含增塑剂的特别是Eudragit NE型聚合物的甲基丙烯酸酯涂料是优选的，以增强药物 - 树脂复合物的药物释放的控制。还包括包含涂覆的树脂形式的液体制剂和抑制降解的螯合剂。

6. 发明申请

WO2009099568A1 APPLICABLE FLUORESCENCE OF DIAMONDOIDS 审中-公开
标题翻译： DIAMONDOIDS适用的荧光
公开(公告)号：WO2009099568A1
公开(公告)日：2009-08-13
申请号：PCT/US2009/000618
申请日：2009-01-30
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , JUSTUS-LIEBIG-UNIVERSITAET GIESSEN , LIU, Zhi , KELLY, Michael, A. , MELOSH, Nicholas, A. , SHEN, Zhi-Xun , FOKIN, Andrey, A. , SCHREINER, Peter, R. , CLAY, Will
发明人： LIU, Zhi , KELLY, Michael, A. , MELOSH, Nicholas, A. , SHEN, Zhi-Xun , FOKIN, Andrey, A. , SCHREINER, Peter, R. , CLAY, Will
IPC分类号： H05B33/14
CPC分类号： H05B33/14 , C09K11/06 , C09K2211/1007 , H01L31/02322 , H01L31/055 , H01L51/5012 , Y02B20/181 , Y02E10/52
摘要： Provided is a fluorescent diamondoid material which when energized, either by an electric field or by high energy radiation, emits light. The light emitted is generally in the visible range. The diamondoid material can be fine tuned by internal or external doping. The fluorescent materials comprised of diamondoids, have applications in several fields. One application is in solar cells where these materials can be used to improve the overall efficiency of the device. A second application is in indoor lighting where the materials can be used to efficiently produce white light. This can be done by either using the material as a fluorescent medium for a UV light source, in an electroluminescence device, or by using the material as part of an organic light emitting diode (OLED).
摘要翻译：提供了一种荧光金刚石材料，当通过电场或通过高能量辐射被激发时，其发光。发出的光通常在可见光范围内。金刚石材料可以通过内部或外部掺杂进行微调。由金刚石组成的荧光材料在几个领域都有应用。一种应用在太阳能电池中，其中可以使用这些材料来提高器件的整体效率。第二个应用是室内照明，其中材料可以用于有效地产生白光。这可以通过使用材料作为UV光源的荧光介质，电致发光器件，或通过使用该材料作为有机发光二极管（OLED）的一部分来完成。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式